<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419964</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-VTL-03(09/11)</org_study_id>
    <nct_id>NCT01419964</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ACH24 in the Treatment of Vitiligo</brief_title>
  <official_title>Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel&#xD;
      group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of&#xD;
      achromatic areas in patients with vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of ACH24 compared to placebo in the treatment of&#xD;
      vitiligo.The present study aims to register a new product in the country, the ACH24 for the&#xD;
      treatment of vitiligo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The Brazilian regulatory agency - ANVISA has requested the cancellation of the phase 3 study&#xD;
    for conducting a phase 1 study first.&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation of the affected area assessed by VASI (vitiligo area scoring index).</measure>
    <time_frame>Baseline compared to the end of 18 months of treatment</time_frame>
    <description>It is considered successful treatment a repigmentation of greater than or equal to 50% of the affected area assessed by VASI (vitiligo area scoring index).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Baseline and each 12 weeks of treatment (V0, V3, V6, V9, V12, V15, V18)</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.</measure>
    <time_frame>Will be evaluated during whole study, at the baseline and after 18 months of treatment</time_frame>
    <description>Collection of safety data throughout the whole study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Group 01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 02</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 01</intervention_name>
    <description>ACH24</description>
    <arm_group_label>Group 01</arm_group_label>
    <other_name>ACH24</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 02</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 02</arm_group_label>
    <other_name>PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes, aged between 18 and 65 years, remaining the feasibility of a&#xD;
             legal guardian in accordance with need, able to understand and provide written&#xD;
             informed consent and able to allow compliance at the treatment and the requirements of&#xD;
             the protocol;&#xD;
&#xD;
          -  Presence of generalized vitiligo;&#xD;
&#xD;
          -  Able to comprehend and willing to provide written informed consent in accordance with&#xD;
             institutional and regulatory guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  Inflammatory diseases;&#xD;
&#xD;
               -  Alopecia Areata;&#xD;
&#xD;
               -  Diabetes Type I;&#xD;
&#xD;
               -  Asthma;&#xD;
&#xD;
               -  Collagen disease;&#xD;
&#xD;
               -  Atopic dermatitis;&#xD;
&#xD;
               -  Psoriasis;&#xD;
&#xD;
               -  Autoimmune thyroid disease (self reported). ¬ Thyroid problems (represents 15% of&#xD;
                  people with vitiligo), exclude only those who need to do treatment with&#xD;
                  corticosteroid or immunosuppressive.&#xD;
&#xD;
          -  Women of childbearing age who had tested positive for pregnancy, or who do not use&#xD;
             acceptable contraceptive method, or do not agree to practice reliable contraception&#xD;
             during the study;&#xD;
&#xD;
          -  Woman in pregnancy or lactation period;&#xD;
&#xD;
          -  Known allergic reaction against the phytomedicine as assessed by medical history;&#xD;
&#xD;
          -  Patient that is taking any prohibited medication (Item 9.3);&#xD;
&#xD;
          -  Participation in last one year of clinical protocols, unless it can be direct benefit&#xD;
             to subject;&#xD;
&#xD;
          -  Any finding of clinical observation (anamnesis and physical exam) laboratory&#xD;
             abnormality (eg, blood glucose, blood count), disease (for example, liver,&#xD;
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may&#xD;
             endanger the subject or interfere with the endpoints of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAIO CASTRO, PHYSICIAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>PUNTIFÍCIA UNIVERSIDADE CATÓLICA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80010-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Macular depigmentation</keyword>
  <keyword>Stachytarpheta cayensensis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

